Table 2.

Trials evaluating glaucoma medical treatment categorized by treatment strategy: IOP lowering, vascular or neuroprotective.

Year	IOP lowering	Vascular	Neuroprotective
Before 2000	9 (69%)	2 (15%)	2 (15%)
2000–2004	33 (92%)	2 (6%)	1 (3%)
2005–2009	152 (94%)	4 (2%)	5 (3%)
2010–2014	187 (95%)	4 (2%)	6 (3%)
2015–2019	89 (86%)	1 (1%)	14 (13%)
2020	15 (79%)	2 (11%)	1 (5%)
Total	485 (92%)	15 (3%)	29 (5%)

IOP-lowering agents cover the vast majority of clinical trials in glaucoma. A total of 485 (92%) evaluated IOP-lowering treatments, 15 (3%) evaluated drugs acting on microvascular blood flow, and 29 (5%) trials examined neuroprotective treatments.